Award
Advance the development of SCY-247, a novel antifungal currently in Phase 1 clinical trials, for the treatment of invasive candidiasis and prophylaxis of invasive fungal disease as oral and IC formula
- Awarded to
- Not stated
- Agency
- Barda - Aspr / Daappo / Barda Dcma
- Estimated value
- $213,943,726
Key dates
- Posted
- September 25, 2026
- Award date
- September 25, 2026
Who is this buyer
Organization
Buying history
- Records9 total
- Opportunities / awards4 / 3
- Value range$18,634,311 – $213,943,726
- ActiveJuly 31, 2026 – October 26, 2026
What they buy
- Clinical (7)
- Administrative (2)
Set-asides used
- No Set aside used (6)
Who holds their work today
- GVS FILTRATION INC.1 win · $23,307,780 · last June 12, 2020
- ALLOSOURCE1 win · $18,634,311 · last September 30, 2022
Also open from this buyer
- Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & ResponseDue November 20, 2026 · Clinical
- Automated Ultrasound-Based, Super Intelligence (SI)-Enabled Fracture DetectionDue November 18, 2026 · Clinical
- Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & ResponseDue November 20, 2026 · Clinical
- Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & ResponseDue October 30, 2026 · Administrative
View source document →
Source link on sam.gov.
Source record
- Buyer type
- Federal
- Jurisdiction
- Federal (US)
- Category
- Clinical
- Set-aside
- Not stated
- NAICS
- Not stated
- PSC
- Not stated